Cyclic-di-GMP diammonium c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium|cas:609343-82-0|西域试剂

Cyclic-di-GMP diammonium c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium,98.18%

产品编号：Bellancom-107780B| CAS NO：609343-82-0| 分子式：C₂₀H₃₀N₁₂O₁₄P₂| 分子量：724.47

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-107780B		￥2500.00	杭州北京（现货）
Bellancom-107780B		￥7500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cyclic-di-GMP diammonium c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium

产品介绍

Cyclic di-GMP (c-di-GMP) diammonium 是一种 STING 激活剂和无处不在的第二信使，调节生物膜的形成、运动和各种细菌的毒力。

生物活性

Cyclic di-GMP (c-di-GMP) diammonium is a STING activator and a global bacterial second messenger, which regulates biofilm formation, motility, and virulence in diverse bacterial species.

体外研究

Cell Proliferation Assay

Cell Line:	H508 cells
Concentration:	0.5-50 µM
Incubation Time:	5 days
Result:	Reduced basal H508 cell proliferation by approx 15%, even inhibited acetylcholine- and EGF-induced cell proliferation.

Cell Viability Assay

Cell Line:	Jurkat cells
Concentration:	50 µM
Incubation Time:	24 h
Result:	Specifically induced of CD4 (no effect on the expression of CD8), with a 6.3-fold upregulation over control and in a dose-dependent manner.

Cell Cycle Analysis

Cell Line:	Jurkat cells
Concentration:	50 µM
Incubation Time:	24 h
Result:	Increased the percentage of cells in S-phase by 79%, with almost complete disappearance of G2/M-phase cells which decreased by 93%.

体内研究
(In Vivo)

Animal Model:	C57BL/6 (B6) mice (8- to 10-week-old).
Dosage:	100 µg/per
Administration:	Intravenous injection; two sequential vaccinations 9 days apart; combine with TriVax.
Result:	Significantly higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 µg hgp100 or 100 µg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC). Enhanced the anti-tumor activity of TriVax.

体内研究

Animal Model:	C57BL/6 (B6) mice (8- to 10-week-old).
Dosage:	100 µg/per
Administration:	Intravenous injection; two sequential vaccinations 9 days apart; combine with TriVax.
Result:	Significantly higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 µg hgp100 or 100 µg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC). Enhanced the anti-tumor activity of TriVax.

体内研究

Animal Model:	C57BL/6 (B6) mice (8- to 10-week-old).
Dosage:	100 µg/per
Administration:	Intravenous injection; two sequential vaccinations 9 days apart; combine with TriVax.
Result:	Significantly higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 µg hgp100 or 100 µg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC). Enhanced the anti-tumor activity of TriVax.

性状

Solid

溶解性数据

In Vitro:

H₂O : 50 mg/mL (69.02 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.3803 mL	6.9016 mL	13.8032 mL
5 mM	0.2761 mL	1.3803 mL	2.7606 mL
10 mM	0.1380 mL	0.6902 mL	1.3803 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶